Table 3.
Studies investigating the efficacy and safety of adding PEG to SRLs in patients with uncontrolled acromegaly
| Design of the study | N. of patients | Length of the study, median (range) | Mean age (SD) | SRL treated patients (%) | IGF-1 at baseline, mean (SD) | PEG dose, median (range) | IGF-1 at EOS, mean (SD) | Patients with normal IGF-1 at EOS (%) | TLEE (%) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Feenstra et al. [90] | Prospective | 19 | 42 weeks | 51 years (12.6) |
Lanreotide ATG 120 mg/4 weeks (81 %) Octreotide LAR 30 mg/4 weeks (19 %) |
510 ng/ml (229) | 60 mg weekly (40–80 mg) | 187 (92) | 95 | 38 |
| Neggers et al. [91] | Prospective | 32 | 138 weeks (35–149) | 53 years (12.8) |
Lanreotide ATG 120 mg/4 weeks (69 %) Octreotide LAR 30 mg/4 weeks (31 %) |
428 ng/ml (220) | 60 mg, weekly or biweekly (40–160) | 137 ng/ml (47) | 100 | 34 |
| Van der Lely. [92] | Prospective | 57 | 28 weeks | 51.6 years (12.7) | Lanreotide ATG 120 mg/4 weeks (100 %) | NA | 60 mg, weekly or biweekly (40–120) | NA | 57.9 | 11 |
| Jorgensen et al. [93] | Prospective | 11 | 12 weeks | 46 years (NA) | Octreotide LAR 30 mg/2-4 weeks (100 %) | 458 ng/ml (67) | 15 mg daily | 195 ng/ml (24) | 91 | NA |
| Bianchi et al. [95] | Retrospective | 27 | 30 weeks (6–72) | 31 years (median age at diagnosis) |
Lanreotide ATG 120 mg/4 weeks (63 %) Octreotide LAR 30 mg/4 weeks (37 %) |
661 ng/ml (162) | 20 mg daily (10–40) | 372 ng/ml (216) | 55.5 | 11.1 |
SRLs somatostatin receptor ligands, PEG Pegvisomant, EOS end of study, TLEE transient liver enzyme elevation